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Abstract
Background: The concept of shared-decision-making is a well-established approach to increase the participation of
patients in medical decisions. Using lifetime risk or time-to-event (TTE) formats has been increasingly suggested as
they might have advantages, e.g. in younger patients, to better show consequences of unhealthy behaviour. In this
study, the most-popular ten-year risk illustration in the decision-aid-software arribaTM (emoticons), is compared
within a randomised trial to a new-developed TTE illustration, which is based on a Markov model.
Methods: Thirty-two General Practitioners (GPs) took part in the study. A total of 304 patients were recruited and
counseled by their GPs with arribaTM, and randomized to either the emoticons or the TTE illustration, followed by
a patient questionnaire to figure out the degree of shared-decision-making (PEF-FB9, German questionnaire to
measure the participation in the shared decision-making process, primary outcome), as well as the decisional
conflict, perceived risk, accessibility and the degree of information, which are all secondary outcomes.
Results: Regarding our primary outcome PEF-FB9 the new TTE illustration is not inferior compared to the well-
established emoticons taking the whole study population into account. Furthermore, the non-inferiority of the
innovative TTE could be confirmed for all secondary outcome variables. The explorative analysis indicates even
advantages in younger patients (below 46 years of age).
Conclusion: The TTE format seems to be as useful as the well-established emoticons. For certain patient populations,
especially younger patients, the TTE may be even superior to demonstrate a cardiovascular risk at early stages. Our
results suggest that time-to-event illustrations should be considered for current decision support tools covering
cardiovascular prevention.
Trial registration: The study was registered at the German Clinical Trials Register and at the WHO International Clinical
Trials Register Platform (ICTRP, ID DRKS00004933); registered 2 February 2016 (retrospectively registered).
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Background
Shared-decision-making (SDM) of patients and health
professionals is increasingly becoming the norm for
health related decisions. SDM was formulated in the
mid-nineties by a Canadian working-group [1]. It is de-
fined as a process of interaction between patient and
physician, both equally and actively participating, well-
informed, with the goal to achieve a common agreement
based on the information available [2]. Studies show that
an increased participation in the decision-making process
leads to a greater satisfaction of doctors and patients and
to a better adherence and clinical outcomes [3, 4].
Decision-aids are designed to help patients make in-
formed choices by delivering evidence-based information
on options and outcomes, e.g. regarding cardiovascular
events [5]. They typically cover diagnostic, therapeutic
and preventive decisions and are also able to inform the
counselling process as they can be delivered in different
formats before, during or after the consultation [6].
Decision-aids are reported to increase knowledge, re-
duce decisional conflict, cause greater satisfaction with
decision-making, support more realistic expectations,
achieve a greater likelihood of being able to make a deci-
sion, result in an increased association between patient
values and decisions, support patient participation, and
enhance communication between physicians, patients
and their relatives [7, 8].
Cardiovascular diseases are a burden for all healthcare
systems, especially in the Western world. Thus, predicting
cardiovascular risk and tailoring preventive efforts accord-
ingly is recommended by national guidelines [9, 10].
Prediction tools are used for this purpose to demon-
strate risk and might initiate behavioural change. They
usually provide individualized absolute risk estimates for
a limited time period, such as 10 years. This format has
been criticized, however, for underestimating high-risk
constellations in the young and middle aged [11–13].
These age groups may have unfavourable risk profiles
relative to their age group. However, since their absolute
risk is still low, this does not become obvious and an op-
portunity for early intervention may be missed [11]. To
overcome this problem, lifetime-risk and time-to-event
formats have been suggested [9, 11–15].
In order to systematically compare both formats, we
developed two risk-displays as part of the computerized
decision-aid arribaTM. The decision-aid-software is well-
established in Germany [16] and being introduced also
in other European countries. It has been extensively
tested and found to be a valuable tool in primary care
practice [17–20].
Within arribaTM, the calculation of absolute cardiovas-
cular risks is based on the Framingham risk algorithm
[21, 22]. The TTE-displays evaluated in this study based
on a Markov-model [23], which was constructed for the
purpose of our study (unpublished data). A Markov model
is an iterative process where patients are assumed to stay
in one cycle (i.e., a defined health state) for a certain time
and then make a transition to another cycle. Markov
models are useful when a decision problem involves risk
that is continuous over time, when the timing of events is
important, and when important events may happen more
than once. Model parameters and justification are avail-
able upon request.
The 10-year-absolute risk format can be visualized
with emoticons (Fig. 2). For the time to event prediction,
we developed a display based on a time bar combined
with a point estimated for possible events (Fig. 3). These
displays emerged as the most accessible and accepted
from a series of exploratory studies comparing different
presentation formats for cardiovascular risk. (unpublished
data).
Following the guidelines for complex interventions
[24–26], we aim to compare the new TTE illustration
with the established emoticons looking at the degree of
SDM in the consultation process and various secondary
outcomes, amongst others the decisional conflict and ac-
cessibility. Additionally, we closely look at age-dependent
differences to figure out if the hypothesis mentioned above
regarding a potential advantage of a lifetime risk illustra-
tion in younger patients.
Methods
Design and setting
This prospective, cluster-randomized trial was performed
in general practices in the greater area of Marburg,
Germany between October 2012 and January 2013. The
study was performed in accordance with the Declaration
of Helsinki and approved by the research ethics committee
of the University of Marburg. The study was registered
at the German Clinical Trials Register (DRKS-ID:
DRKS00004933).
GP recruitment
A convenience sample of GPs who are affiliated with the
Department of Primary Care at the University of Marburg
were invited by mail to take part in the study (see Fig. 1
for recruitment details). Thirty-two GPs in twenty-eight
practices agreed to participate in the study. They took part
in meetings to be trained in study procedures and the use
of both ways of showing risk in arribaTM, the emoticons
and the TTE, Each GP received advice on how to commu-
nicate risk according to the respective risk format and
how to make use of the material in arribaTM. Immediately
after the training they completed a questionnaire regard-
ing personal characteristics and workload as well as prior
experience with the decision-aid arribaTM. Finally, they re-
ceived a booklet summarizing the content of the training
for further reading and individual preparation. The training
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was followed by an office visit of a study nurse in order to
install the study software, handover the study material and
clarify any issues with the GPs. In addition, GPs could con-
tact the study group anytime in case of problems or doubts
about any issue during the study period. The GPs received
a financial compensation for every patient included in the
study.
Patient recruitment
Patients were eligible for the study if they were aged 30
to 80 years and the GP felt a need to discuss behavioral
change regarding cardiovascular risk. This could be, for
example, the biannual health check “CheckUp 35+”, of-
fered to adults above 35 years, a disease management
program (DMP) consultation or a discussion of medica-
tion after specialist consultation. Patients were also eli-
gible, if they addressed cardiovascular risk and possible
prevention themselves. The latter could include medica-
tions (statins, low-dose aspirin, antihypertensive drugs or
dose adjustments), dietary changes, exercise or smoking.
Patients were excluded if they were – according to the
judgement of the GP – significantly impaired cognitively,
had insufficient knowledge of the German language or
had no interest in taking an active part in the decision
process.
Interventions
Immediately after giving their informed consent, patients
were randomized to consultation with the emoticons (Fig. 2)
or the TTE illustration (Fig. 3). GPs entered a study ID into
the decision support software, which automatically allo-
cated each patient into one of the two conditions according
to an a priori randomised sequence. GPs learned about
each patient’s allocation by the illustration displayed by the
software. They then started a discussion with their patients
on the basis of the allocated display, i.e. either emoticons,
or TTE, respectively. After the consultation, patients were
asked to fill in a questionnaire covering the immediate
outcome assessments. GPs recorded the decision made,
such as specific medications, dose adjustments, behavioral
measures or no change at all. Three months later, patients
were contacted by telephone to assess their adherence.
The results of these follow-up interviews will be published
elsewhere.
Fig. 1 Flowchart of participation
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Outcomes
Primary outcome
The main objective of the study was to evaluate the
non-inferiority of the new TTE illustration compared to
the emoticons regarding their impact on SDM. This was
operationalized by the German questionnaire on shared-
decision-making (SDM), the PEF-FB-9 (PEF is the Ger-
man acronym for SDM). This instrument [27] measures
the degree of participation which patients experience in
the consultation as seen by the patient him- or herself.
The instrument has been evaluated for its psychometric
characteristics [27]. Moreover, it has been applied in
various studies on different patient groups and clinical
topics [28–30].
Secondary outcomes
In addition to the primary endpoint mentioned above,
we evaluated several secondary endpoints. First, the de-
cisional conflict was assessed by the German version of
the Decisional Conflict Scale (DCS) [31, 32]. The DCS
Fig. 2 Emoticon-interface of the arribaTM decision-aid (a Medical history taking1, b visualization of treatment options2)
Footnote:1On the left, information regarding the medical history must be filled in, which is (from top to bottom): gender, age, smoking-status,
presence of manifest arteriosclerosis, positive family history, taking of antihypertensive medications, systolic blood pressure, total cholesterol
level, high density lipoproteins (HDL) level, presence of diabetes, HbA1c level.On the right, the emoticons are displayed, accompanied by the
following headline: “Out of 100 men with the same risk profile, 25 will suffer a myocardial infarction or stroke within the next 10 years.”2On
the left, the treatment options are shown, which are (from top to bottom): behavioral changes, like smoking cessation, nutrition, sports and
on the other hand drug treatment, i.e. statins, antihypertensive drugs, aspirin, metformin.On the right, the emoticons are displayed, accompanied by
the following headline: “Out of 100 treated men with the same risk profile, 14 will suffer a myocardial infarction or stroke within the next 10 years.”The
risk reduction (here due to nutrition modification and sports) is indicated with orange-colored emoticons
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encompasses sixteen items, measured on a five-point
Likert scale. The decisional conflict scale measures per-
sonal perceptions of uncertainty in choosing options,
modifiable factors contributing to uncertainty such as
feeling uninformed, unclear about personal values and
unsupported in decision making and finally effective de-
cision making such as feeling the choice is informed,
values-based, likely to be implemented and expressing
satisfaction with the choice [33].
Second, the degree of information was measured, using
the German version of the Preparation for Decision-
Making Scale (PDMS-D) [34]. The PDMS-D contains ten
items and includes two dimensions: Seven items are re-
lated to the preparation for the decision-making itself and
three items capture the patient’s preparation for the GP
consultation. According to the authors of the PDMS Prep-
aration for Decision Making is defined as ‘a patients’ per-
ception of how useful a decision aid or other decision
Fig. 3 TTE-interface of the arribaTM decision-aid (a Medical history taking3, b visualization of treatment options4)
Footnote:3On the left, the information regarding the medical history must be filled in, which is (from top to bottom): gender, age, smoking-
status, presence of manifest arteriosclerosis, positive family history, taking of antihypertensive medications, systolic blood pressure, total cholesterol
level, high density lipoproteins (HDL) level, presence of diabetes.On the right, the TTE graph is displayed, accompanied by the following headline: “A
62y old man with the same risk profile could suffer a myocardial infarction or stroke in in average time of 8 years form now (at 70y of age).4On the left,
the treatment options are shown, which are (from top to bottom): behavioral changes, like smoking cessation, nutrition, sports and on the other hand
drug treatment, i.e. statins, antihypertensive drugs, aspirin.On the right, TTE graphs are displayed, accompanied by the following headline: “A 62y old
treated man with the same risk profile could suffer a myocardial infarction or stroke in in average time of 9 years form now (at 71y of age).The risk
reduction (here due to sports) is indicated with the orange-colored timeline.The following statistical information is added: “35,8% of this group
suffer a myocardial infarction or stroke at all”
Adarkwah et al. BMC Medical Informatics and Decision Making  (2016) 16:152 Page 5 of 12
support intervention is in preparing the respondent to
communicate with their practitioner at a consultation visit
and making a health decision“ [35].
While the PDMS-D focuses more on the information
material used in the counseling process, the DCS ac-
counts for the quality of the decision.
Third, subjective accessibility of the information was
assessed using an adaptation of the scale by Gaissmeier
and colleagues [36]. This encompasses four questions at
a five-point Likert scale, ranging from 1 (not at all) to 5
(very much), asking about the four aspects of information:
comprehensibility, usefulness, seriousness and intuitive
accessibility. Answers were averaged to generate one
accessibility score for each participant.
Finally, patients were shown two visual analog scales
in order to rate on the one hand the importance of
avoiding a cardiovascular event and on the other hand
to estimate their own cardiovascular risk.
Statistical analyses
All statistical calculations were performed with IBM
SPSS [37]. We calculated means, standard deviations
and frequencies for the descriptive data. The hypotheses
concerning the non-inferiority of the TTE illustration
are tested by means of confidence intervals based non-
inferiority tests according to the following equation:
H1 : μ1‐μ2 < ε
with μ1 as the score mean or the total score of the par-
ticular question in the emoticon group and μ2 accord-
ingly in the TTE group, while ε is the pre-specified
non-inferiority margin. We defined the boundary ε, as
1/10 of the range of the respective questionnaire-score.
The non-inferiority tests are performed by calculating a
one-sided 95%-confidence interval for the difference
between μ1 and μ2. If the upper bound of this confi-
dence interval is less than ε, it can be concluded that
the TTE illustration is not inferior compared to the
emoticons. In order to examine the importance of the
differences between the two graphic dentitions, effect
sizes (Cohen’s D) are calculated [38].
We compare the two illustrations in respect to one
primary outcome variable, PEF-FB9, and additionally to
several secondary outcome variables (amongst others the
decisional-conflict, preparation for decision-making, risk
perception). An additional secondary analysis is the
exploration of a potential superiority of the new TTE
illustration in younger patients, less than 46 years of
age. This is investigated by testing the interaction term
of age-group and illustration in a two-factorial analysis of
variance, with the factors “age-group” and “illustration”.
For this analysis the population is split up into two age-
groups, <=45 years and > 45 years. Finally, for the patients
younger than 46 years, the average of all questions or test-
scores will be compared descriptively regarding the two
illustrations.
In line with the exploratory nature of the tests con-
cerning the secondary outcome variables, we apply no
alpha-correction for multiple testing. If the confidence-
interval-based test happens to suggest superiority of the
new TTE illustration, it is justifiable to state the result of
superiority [39].
Characteristics of the patients are demonstrated by
mean, standard errors in metric variables, frequencies
and percentages in categorical variables. Non-inferiority
hypotheses are performed by means of one-sided 95%
confidence intervals. The alternative hypothesis of non-
inferiority is accepted, if the lower bound of the confi-
dence interval for the difference of μ1 μ is < ε. Superiority
of the TTE in respect of the decisional conflict in young
patients is explored by means of a two-way ANOVA. A
significant interaction term of age-group and presentation
would indicate superiority of the TTE illustrations over
the emoticons.
Results
Thirty two GPs in 28 practices included an average of
9.5 patients (range from 3 to 15) which resulted in a
sample of 304 study participants (Fig. 1). 147 patients
were shown emoticons and 157 patients received their
risk information on the basis of the TTE illustration. The
characteristics of the two groups (emoticons and TTE) are
shown in Table 1. This is a sample of predominantly older,
male patients with known risk factors and comorbidities.
Apparently this is the group, where GPs and/or patients feel
a need to discuss cardiovascular prevention, both study
arms were well-balanced regarding sociodemographic and
clinical variables.
Primary outcome
The mean difference of emoticons and TTE regarding
the PEF-FB9 is −1.69 with a 90%-confidence interval
ranging from −5.51 to 2.12. Thus, the upper limit of the
90%-confidence interval is clearly below the pre-specified
non-inferiority margin ε, which is 10 (10% of the scale’s
total range of 100). In addition, the effect size according to
Cohen is d = 0.09, which represents a small effect (see
Table 2). Taken together, these two results confirm the
non-inferiority of the TTE-display. Regarding our primary
outcome PEF-FB9 the TTE illustration is not inferior com-
pared to the emoticons. There is no significant difference
to be found between the two ways of presenting risk, tak-
ing the whole study population into account.
Secondary outcomes
The results of all secondary outcomes are shown in Table 2.
Both the confidence intervals as well as the small effect
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sizes show that the non-inferiority of the innovative TTE
could be confirmed also for the remaining outcome vari-
ables. In addition, both illustrations were rated as highly
accessible.
Looking at the risk perception, the subjective risk was
rated significantly higher in the TTE group compared to
the emoticons. Here, the upper limit of the 90% confi-
dence interval for μ1-μ2 is even smaller than 0, which
shows the superiority of the TTE with respect to the risk
perception. For this item, the effect size is 0.45, which
represents a medium effect.
Interaction with age
As expected, the two age-groups vary in the numbers of
risk factors, and their composition. Diabetes and getting
antihypertensive treatment is more common in the eld-
erly. Additionally, the percentage of smokers is higher in
the elderly, while there are no significant differences in
the proportion of male participants or migrants (see
Table 3 for further details). The two illustrations have
different effects depending on the patient’s age. We
could see that providing information about the time-to-
event instead of giving a 10-year absolute risk leads to a
significant difference in the perceived risk. This was
mainly the case in younger patients (<46 years) and shows
that those patients counseled with the TTE experience a
higher subjective risk to suffer a cardiovascular event
(Additional file 1: Table S1, Fig. 4). This however does not
impact the importance to avoid a cardiovascular event
overall for which the interaction was not significant. For
instance, this is most likely due to a ceiling effect.
In the explorative analyses, interactions of age and
illustration were tested in a two-factorial ANOVA.
Here, we could find four other outcome variables with
a significant interaction, i.e. the intuitive accessibility
(Additional file 2: Table S2, Fig. 5), the total DCS
score (Additional file 3: Table S3, Fig. 6), the DCS ef-
fective decision subscore (Additional file 4: Table S4,
Fig. 7) and the PDMS-D subscore “preparation for the
GP consultation” (Additional file 5: Table S5, Fig. 8).
Here, the superiority of the TTE could be confirmed
in both patient groups with respect to age, in which
the difference in the group of younger patients is
higher. For instance, looking at the DCS, scores in the
group of younger patients are remarkably higher than
scores for older patients for the TTE, while they differ
less for the emoticons (Additional file 3: Table S3).
This accounts for the total DCS as well as for all DCS




Regarding our primary outcome PEF-FB9 the new TTE
illustration is not inferior compared to the emoticons
(whole sample). Furthermore, the non-inferiority of the
innovative TTE could be confirmed for all secondary
outcome variables. The explorative comparison of young
and old patients even indicates advantages, e.g. a higher
Table 1 Characteristics of the study population
Emoticons Time-to-event (TTE)
Age (yr), M (SD) 58.01 (10.66) 57.83 (11.033)
Proportion of immigrants, n (%) 11 (8) 14 (9)
Proportion of pts with low level of education1 66 (45%) 67 (43%)
Gender: male, n (%) 88 (60%) 87 (55%)
Known hypertension, n (%) 36 (25%) 45 (29%)
Total cholesterol level > 200 mg/dl n (%) 99 (67%) 115 (73%)
HDL < 40 mg/dl, n (%) 25 (17%) 21 (13%)
Known Diabetes, n (%) 43 (29%) 41 (26%)
Current smoker, n (%) 40 (27%) 43 (27%)
Male age >55, female age >65, n (%) 67 (46%) 70 (45%)
Known vascular disease2, n (%) 15 (10%) 14 (9%)
Family history of vascular disease3, n (%) 49 (33%) 54 (34%)
Hypertension medication, n (%) 84 (57%) 76 (48)
Mean number of risk factors 3.08 (1.57) 3.01 (1.33)
Patients with arriba experience, n (%) 15 (10%) 17 (11%)
Yr year, pts patients, HDL high density lipoprotein cholesterol
1Low level of education definded as no general certificate of secondary education
2Evidence of either coronory heart disease, stroke or peripheral arterial occlusive disease
3At least one first-degree relative with coronary heart disease, occured before the age of 55 in men, and 65 in women
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risk perception, of the TTE in younger patient groups
(below 46 years of age).
Strengths and limitations
Our study has some limitations: First, the reasons for
higher scores in the DCS and the PDMS-D scale in the
younger population are not fully explained. We can only
speculate about these results and reasons for the differ-
ences. Further qualitative research especially looking at
younger patients and their motivation would be neces-
sary to shed light on these issues. This is directly related
to and caused by the second limitation. Our study sam-
ple was drawn from practice attenders with a need to
discuss cardiovascular prevention. It therefore reflects
the demographic and morbidity features of this group.
As a result, younger persons were underrepresented. In
order to replicate and strengthen these results as well as
further investigate the younger population and the mecha-
nisms that underlie the results, which were mentioned
and discussed above, future studies should include higher
numbers of young patients. Third, the TTE representation
in our arribaTM study version did not allow for all combi-
nations of risk-reducing interventions that are possible. As
mentioned above, a complex Markov model is underlying
this risk format, but could illustrate only one intervention
in isolation but no combination of several treatments.
Those combinations are not very likely, but nevertheless
possible and the decrease of risk needs to be illustrated for
the patient.
Despite these limitations we still think that our study
provides valid estimates regarding the outcome measure.
Our study is the first study to investigate real patients in
the setting of a GP consultation and regarding CV deci-
sions concerning themselves looking at the PEF-FB 9 and
Table 2 Results of the non-inferiority tests
















Total score (primary outcome)
81.88 (20.58) 83.57 (18.12) 100 10 2.12 yes 0.09
Risk perception* 4.06 (2.344) 5.22 (2.83) 10 1 −0.659 Yes, even
superiority
0.45
Importance of avoiding a CV
event
8.84 (2.39) 9.06 (1.95) 10 1 0.19 yes 0.10
Accessibility
Total Score
18,10 (1,835) 17,78 (2,598) 16 1.6 0.74 yes −0.14
Subscore “comprehensibility” 4.69 (0.52) 4.56 (0.719) 4 0.4 0.245 yes −0.21
Subscore “usefulness” 4.57 (0.598) 4.43 (0.74) 4 0.4 0.268 yes −0.21
Subscore “seriousness” 4.4 (0.669) 4.46 (0.75) 4 0.4 0.074 yes 0.08
Subscore “intuitive accessibility” 4,40 (0.79) 4,34 (0.78) 4 0.4 0.195 yes −0.08
PDMS-D
total score
72,32 (19.57) 73.57 (19.89) 40 4 2.6 yes 0.06
subscore preparation for
decision-making
74.34 (19.08) 74.74 (19.3) 40 4 3.29 yes 0.02
subscore preparation for
GP consultation
68.91 (24.0) 70.5 (25.0) 40 4 3.16 yes 0.06















DCS Total score 15.38 (13.96) 14,77 (12.36) 100 −10 −2.0 yes −0.05
Informed Subscore 16,84 (17.79) 16.23 (16.01) 100 −10 −2.64 yes −0.04
Values Clarity Subscore 14.81 (16.71) 13.64 (13.96) 100 −10 −1.76 yes −0.08
Support Subscore 16,19 (15.93) 17,43 (16.45) 100 −10 −4.4 yes 0.08
Uncertainty subscore 15,57 (17.02) 14,73 (15.69) 100 −10 −2.27 yes −0.05
Effective decision subscore 13.66 (15.85) 13.74 (15.31) 100 −10 −3.07 yes 0.00
DCS: Decisional Conflict Scale, high score stands for high level of decisional conflict
PEF-FB 9 Shared decision-making questionnaire, 9 items; high score stands for high level of patient involvement
CV cardiovascular, PDMS-D Preparation for Decision-Making Scale – German version, GP general practitioner
*Risk perception is significantly higher in the TTE illustration group compared to the emoticons (p < 0.005)
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the other secondary outcomes mentioned and discussed
in detail above. In fact, issues regarding their own cardio-
vascular risks and preventive options were discussed and
real decisions were taken.
Comparison with existing literature
Literature on the effect of lifetime risk predictions with
respect to cardiovascular risk on patients’ decision-making
is scarce. Hence, it is challenging to assess how risk for-
mats impact on the patient’s motivation to participate in
the decision-making process. Several studies have investi-
gated the impact of a TTE illustration. Advantages with
respect to understanding compared to other formats could
be shown [40–43]. Compared to our work, previous
studies did not consider other representations. A Danish
study asked participants for the level of understanding
and acceptance of a fictional drug treatment in order to
postpone heart attacks. The information was delivered
in a verbal time-to-event exercise with varying time-
frames of postponement. There was no comparison
with another risk format but overall level of under-
standing was high with about 81% of all participants
judging the information as “not difficult” [43]. Further-
more, studies in this filed of research were performed
by a web-based survey and not in the setting of a GP
consultation.
Table 3 Characteristics of the study population, according to age-group
pts < 45 years pts > 45 years p-value
Age (yr), M (SD) 39.79 (3,87) 60,58 (8,27) <0,0005
Proportion of immigrants, n (%) 4 (10,5%) 21 (8%) 0,401
Proportion of pts with low level of education1 11 (28%) 122 (46%) 0.039
Gender: male, n (%) 21 (54%) 154 (58%) 0,608
Known hypertension, n (%) 7 (18%) 74 (28%) 0,245
Total cholesterol level > 200 mg/dl n (%) 23 (59%) 191 (72%) 0.131
HDL < 40 mg/dl, n (%) 8 (21%) 38 (14%) 0.338
Known Diabetes, n (%) 3 (8%) 81 (31%) 0.002
Current smoker, n (%) 16 (41%) 67 (25%) 0.053
Known vascular disease2, n (%) 4 (10%) 9 (9%) 0.775
Family history of vascular disease3, n (%) 16 (41%) 87 (33%) 0.365
Hypertension medication, n (%) 11 (28%) 149 (56%) 0.002
Mean number of risk factors 2.21 (1.32) 3.17 (1.43) 0.229
Patients with arriba experience, n (%) 1 (3%) 31 (12%) 0.096
pts patients, yr year, pts patients, HDL high density lipoprotein cholesterol
1Low level of education definded as no general certificate of secondary education
2Evidence of either coronory heart disease, stroke or peripheral arterial occlusive disease
3At least one first-degree relative with coronary heart disease, occured before the age of 55 in men, and 65 in women
Fig. 4 Risk perception as a function of age-group and illustration Fig. 5 Accessibility as a function of age-group and illustration
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Carling et al. presented the benefit of a fictional anti-
biotic drug in a web-based survey. In detail, one of several
formats was shown to healthy individuals, i.e. the percent-
age of persons with improved symptoms after three days.
The presentation was either done as icon arrays with
smileys, horizontal bars or duration of symptoms as a
horizontal bar (i.e. time until sore throat has subsided).
The latter display was judged the most understandable.
Implications for research and practice
Focusing on younger patients, especially patients at risk,
little research has been performed with respect to car-
diovascular risk prevention in general practice. It seems
quite obvious that counselling young patients with a
ten-year-absolute-risk information might lead to an
underestimation of their lifetime risk, i.e. a significant
lifetime risk will not be detected, even in high-risk pa-
tients. Thus, behavioural change is unlikely to happen in
these cases and prevention mechanisms cannot work
properly. For instance, looking at those younger patients
we could first demonstrate, that the TTE - as mentioned
above – leads to a higher risk perception immediately
after the GP consultation. We assume that this higher
risk perception is due to the fact that a risk, which has
not been considered previously, becomes obvious only
in the context of the GP consultation with TTE. For
younger people, this is seems to be much more relevant
than the conventional ten-year prognosis.
Next, we could show that the decisional conflict was
considerably higher in younger patients confronted with
the TTE compared to the emoticons. In our view, this
shows that the TTE representation in arribaTM raises an
issue that the patient has not been aware of prior the
consultation. In this case, raised decisional conflict
should not necessarily be seen as negative. Future stud-
ies, especially qualitative investigations and quantitative
surveys with prolonged follow-up are needed to explore
these findings further.
Furthermore, results indicate lower scores in the
PDMS-D in the TTE group, i.e. the experienced degree
of information is lower in young patients counselled
with the TTE. We can speculate about the reasons for
this finding. Maybe young patients did not understand
the representation that well, or not enough options for
action could be demonstrated. Hence, looking at the two
dimensions of the PDMS-D, the finding becomes clearer.
The difference is primarily caused by significantly lower
scores in the “preparation for GP consultation” sub-scores
and is therefore not first-order related to the representa-
tion itself.
Fig. 6 DCS (total score) as a function of age-group and illustration
Fig. 7 DCS (effective decision subscore) as a function of age-group
and illustration
Fig. 8 PDMS-D (subscore patients’s preparation for the GP
consultation) as a function of age-group and illustration
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Conclusion
The results of our study show that the illustration of the
event-free survival (TTE) is appropriate for cardiovascu-
lar risk information. Moreover, this illustration offers the
possibility to counsel younger patients adequately, so
that relevant preventive actions can be started despite
absolute risks still being small. The latter is not suffi-
ciently the case with the risk representations that are
currently available and all provide a 10-year prognosis.
Whether the higher decisional conflict in the TTE group
is generated by the improved risk perception, has to be
proven in future studies.
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